CanSino Biologics Inc.
CASBF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.30 | 10.43 | 1.81 | 0.00 |
| FCF Yield | -0.13% | -0.59% | -1.05% | -0.16% |
| EV / EBITDA | 305.93 | 614.64 | 236.19 | -41.54 |
| Quality | ||||
| ROIC | 0.01% | -0.03% | -0.30% | -2.14% |
| Gross Margin | 78.37% | 77.67% | 82.69% | 58.29% |
| Cash Conversion Ratio | 1.11 | -12.93 | 1.20 | -0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.34% | 30.08% | 10.62% | -6.95% |
| Free Cash Flow Growth | 94.99% | 48.32% | -606.97% | 91.57% |
| Safety | ||||
| Net Debt / EBITDA | 8.83 | 59.68 | -39.51 | 0.06 |
| Interest Coverage | 0.04 | 0.00 | 0.00 | -6,767.26 |
| Efficiency | ||||
| Inventory Turnover | 0.19 | 0.16 | 0.07 | 0.41 |
| Cash Conversion Cycle | 625.20 | 724.95 | 1,444.52 | 408.44 |